{"title":"Abstracts of the 23rd Annual North American Cystic Fibrosis Conference, Minneapolis, Minnesota, USA, October 15-17, 2009.","authors":"","doi":"10.1002/ppul.21130","DOIUrl":"https://doi.org/10.1002/ppul.21130","url":null,"abstract":"","PeriodicalId":77317,"journal":{"name":"Pediatric pulmonology. Supplement","volume":"32 ","pages":"109-453"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ppul.21130","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40034696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstracts of the 21st Annual North American Cystic Fibrosis Conference, October 23-25, 2008, Orlando, Florida, USA.","authors":"","doi":"10.1002/ppul.20936","DOIUrl":"https://doi.org/10.1002/ppul.20936","url":null,"abstract":"","PeriodicalId":77317,"journal":{"name":"Pediatric pulmonology. Supplement","volume":"31 ","pages":"105-483"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ppul.20936","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27818681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstracts of the 21st Annual North American Cystic Fibrosis Conference, October 3-6, 2007, Anaheim, California, USA.","authors":"","doi":"10.1002/ppul.20699","DOIUrl":"https://doi.org/10.1002/ppul.20699","url":null,"abstract":"","PeriodicalId":77317,"journal":{"name":"Pediatric pulmonology. Supplement","volume":"30 ","pages":"99-412"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ppul.20699","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26915922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstracts of the 20th Annual North American Cystic Fibrosis Conference, November 2-5, 2006, Denver, Colorado, USA.","authors":"","doi":"10.1002/ppul.20535","DOIUrl":"https://doi.org/10.1002/ppul.20535","url":null,"abstract":"","PeriodicalId":77317,"journal":{"name":"Pediatric pulmonology. Supplement","volume":"29 ","pages":"93-415"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ppul.20535","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26341398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstracts of the 19th Annual North American Cystic Fibrosis Conference, Baltimore, Maryland, USA, October 20-23, 2005.","authors":"","doi":"10.1002/ppul.20312","DOIUrl":"https://doi.org/10.1002/ppul.20312","url":null,"abstract":"","PeriodicalId":77317,"journal":{"name":"Pediatric pulmonology. Supplement","volume":"28 ","pages":"87-373"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ppul.20312","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25294989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"HIV immunology and new therapies.","authors":"Jay K Kolls","doi":"10.1002/ppul.70052","DOIUrl":"https://doi.org/10.1002/ppul.70052","url":null,"abstract":"Despite advances in highly active anti-retroviral therapy (HAART), pulmonary infection with Pneumocystis carinii remains a significant severe opportunistic infection to complicate HIV infection (1;2). P. carinii pneumonia (PCP) is the index infection for AIDS in 2540 percent of cases (1;3). In patients with established AIDS, prophylactic regimens have decreased the overall incidence of PCP, but in most patients this means that PCP is delayed rather than eliminated. For example, in patients with CD4 counts <200/ml, the use of contemporary prophylactic regimens is still associated with an approximate 18% risk of PCP over a 36 month period (4). The widespread use of PCP prophylaxis also means that greater than 80% of PCP cases in current patient cohorts are now breakthrough cases (5). Moreover, in one study of high-risk children, the incidence of PCP has not declined despite continued efforts to identify HIV-infected infants and initiate PCP prophylaxis (6). However, if HAART is successful as determined by an increase in CD4þT-cell count above 200/ml, the data to date show that PCP prophylaxis can be safely discontinued in these individuals (7;8). This is again points to the strong, inverse correlation of CD4þ T cell status and risk of PCP. Unfortunately, not all AIDS patients respond to HAART and drug resistance is emerging (9;10).","PeriodicalId":77317,"journal":{"name":"Pediatric pulmonology. Supplement","volume":" ","pages":"59-61"},"PeriodicalIF":0.0,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ppul.70052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40848335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Inhaled antibiotics.","authors":"Harm Tiddens","doi":"10.1002/ppul.70065","DOIUrl":"https://doi.org/10.1002/ppul.70065","url":null,"abstract":"Chronic bacterial infection of the lower airways is present in most CF-patients early in life. This chronic bacterial infection results in an exaggerated immune response leading to structural damage in the airways and parenchyma. It is more and more recognized that early and aggressive antibiotic treatment can reduce lung damage and improve life expectancy. The most important route to deliver these antibiotics is orally and intravenously. Since the seventies, aerosolized antibiotics have been used to treat CF related lung disease. An important advantage of aerosolized antibiotics is that the antibiotic is directly targeted to the diseased area in the lung. Theoretically, this can be a huge advantage over systemic antibiotic therapy. Firstly, high concentrations in the lung can be obtained. This is important to get effective inhibition or killing of microorganisms. Secondly, only a small proportion of the inhaled antibiotics are absorbed from the lungs. Therefore, the systemic burden is minimal and systemic sideeffects are reduced. Thirdly, there will be less disturbance of the host microorganisms. Although it is likely that aerosolized antibiotics will have a high efficacy/toxicity ratio, there is a higher risk of pulmonary side-effects. Inhaled substances can act as an irritant or allergen causing inflammation and edema. Whether such local side-effects occur can best be studied in healthy subjects in a phase I dose escalation trial. Next, Phase II and III trials in patients are needed to evaluate the efficacy/ toxicity ratio. In this chapter we will discuss various aspects that influence the efficacy and toxicity of inhaled antibiotics.","PeriodicalId":77317,"journal":{"name":"Pediatric pulmonology. Supplement","volume":" ","pages":"92-4"},"PeriodicalIF":0.0,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ppul.70065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40848348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exhaled breath condensate.","authors":"Matthias Griese","doi":"10.1002/ppul.70034","DOIUrl":"https://doi.org/10.1002/ppul.70034","url":null,"abstract":"The air that we exhale is saturated with water vapor and contains 0.1 to 4 droplets per ml exhaled air. These droplets may have diameters of 0.09 to 3 (m. They are believed to be generated by high velocity air flow which creates shear forces and overcome the adhesion of the fluid to the airway surfaces (1). Thus it appears likely that the composition of the droplets may mirror that of the corresponding airway surface fluid. This may allow noninvasive monitoring of physiological and inflammatory conditions of the lungs. However various practical and theoretical problems have to be overcome before the technique can be applied widely. These include the collection of sufficient material during a reasonable time period, the routine application to subjects of all age groups, and the degree of reproducibility of the results. An important obvious limitation is the large dilution of the droplets by the condensedwater vapor that may also be trapped with the droplets. A contamination with saliva on the one hand and the extremely low concentration of the components of EBC on the other hand which necessitates precise analytical procedures, are major technical challenges. Saliva is a complexmixture of several hundreds of glycoproteins, proteins, hormones, minerals, buffer ions, etc with a protein concentration about 700 (g/ml and aNaCl concentration of about 10mM (2). Thus a 2 (l droplet may contain about 1400 ng of protein and 20 nmol of Na or Cl. At an EBC protein concentration of 10 ng/ml and a salt concentration of 2 nmol/ml, the contamination by tiny droplets of saliva results in 10 or much more fold changes of the original concentrations of EBC. The initial devices used for the collection of EBC were home made apparatus, consisting of a mouth piece, connected to tubing submerge in ice water, used to generate the condensate. A recent study showed no difference of such devices with commercially available equipment, i.e. the EcoSreen by Jäger, Germany, which may overcome problems of standardization of the breathing pattern, expiratory flow, length, material, and diameter of the tubing used. Another recently developed device uses a negative pressure to collect exhaled breath components entirely without cooperation (3). The advantages include an applicability in all age groups (premature infants, elderly, disabled persons), during sleep or at night, during effort and exercise, the avoidance of contamination by saliva and the direct sampling into the storage container. The apparatus is simple, mobile and allows the free selection of material for tubing and tubes. The disadvantages include simultaneous sampling of the nasal compartment, potential contact with the skin of the nose and the collection of only a fraction of the exhaled breath (3). Not many studies have addressed basic questions of analytical procedures, like day to day variability and reproducibility. Using mass spectrometry, Coradi et al. found in 8 subjects assessed on 2 occasions, for malonaldeh","PeriodicalId":77317,"journal":{"name":"Pediatric pulmonology. Supplement","volume":" ","pages":"14-5"},"PeriodicalIF":0.0,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ppul.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40848397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E Baraldi, F Pasquale, G Bonetto, S Carraro, S Zanconat
{"title":"Exhaled gas analysis and airway inflammation.","authors":"E Baraldi, F Pasquale, G Bonetto, S Carraro, S Zanconat","doi":"10.1002/ppul.70035","DOIUrl":"https://doi.org/10.1002/ppul.70035","url":null,"abstract":"One of themost significant advances of recent years lies in our learning that asthma is not a single disease but a spectrum of phenotypes involving different cell types and mediators. We also now know that even clinicallyquiescent asthma can be associated with airway inflammation (1). The development and application of safe and simplemethods for assessingmarkers of inflammation can therefore help us to gain a better understanding of the relationship between the various inflammatory processes occurring in asthma and improve treatment strategies (2). Recently, in keeping with these hypotheses, it has been demonstrated that treatment targeted at controlling airway inflammation markers may be more effective in reducing asthma exacerbations than treatment based on the conventional assessment of symptoms, peak flow and the use of (2 agonists (3). The most extensively studied marker is exhaled nitric oxide (FENO) but recently other volatile gases as carbon monoxide (CO) have been used. In addition several endogenous substances may be detected in exhaled breath condensate (EBC) opening up new prospectives for exhaled breath analysis (2)","PeriodicalId":77317,"journal":{"name":"Pediatric pulmonology. Supplement","volume":" ","pages":"16-9"},"PeriodicalIF":0.0,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ppul.70035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40848398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}